Clinical Policy: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Reference Number: HIM.PA.58
Effective Date: 03.01.18
Last Review Date: 02.20
Line of Business: HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The following agents contain a dipeptidyl peptidase-4 (DPP-4) inhibitor and require prior authorization: alogliptin (Nesina®), linagliptin/empagliflozin (Glyxambi®), linagliptin/empagliflozin/metformin (Trijardy™ XR), and saxagliptin (Onglyza®).

FDA Approved Indication(s)
DPP-4 inhibitors are indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin-containing products are also indicated in adult patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death.

Limitation(s) of use:
• DPP-4 inhibitors should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
• DPP-4 inhibitors have not been studied in patients with a history of pancreatitis.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that DPP-4 inhibitors are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Type 2 Diabetes Mellitus (must meet all):
      1. Diagnosis of type 2 diabetes mellitus;
      2. Age ≥ 18 years;
      3. Member meets one of the following (a or b):
         a. Failure of ≥ 3 consecutive months of metformin, unless contraindicated or clinically significant adverse effects are experienced;
         b. HbA1c drawn within the past 3 months is ≥ 8.5%, and concurrent use of metformin unless contraindicated or clinically significant adverse effects are experienced;
      4. If request is for Glyxambi or Trijardy XR, member meets one of the following (a or b):

a. Failure of ≥ 3 consecutive months of Steglatro™ or Segluromet™, unless both are contraindicated or clinically significant adverse effects are experienced;
b. Member has established cardiovascular disease (e.g., ASCVD or HF) or diabetic nephropathy;
5. If request is for Nesina or Onglyza, failure of ≥ 3 consecutive months of a sitagliptin or linagliptin-containing product (e.g., sitagliptin [Januvia®], sitagliptin/metformin [Janumet®, Janumet® XR], linagliptin [Tradjenta®], linagliptin/metformin [Jentadueto®, Jentadueto® XR]), unless contraindicated or clinically significant adverse effects are experienced;
6. Dose does not exceed the FDA approved maximum recommended dose (see Section V).

Approval duration: 12 months

B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

II. Continued Therapy
A. Type 2 Diabetes Mellitus (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed the FDA approved maximum recommended dose (see Section V).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized: Not applicable
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
AACE: American Association of Clinical Endocrinologists
ACE: American College of Endocrinology
ADA: American Diabetes Association
ASCVD: atherosclerotic cardiovascular disease
DPP-4: dipeptidyl peptidase-4
FDA: Food and Drug Administration
Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>metformin (Fortamet®, Glucophage®, Glucophage® XR, Glumetza®)</td>
<td>Regular-release (Glucophage): 500 mg PO BID or 850 mg PO QD; increase as needed in increments of 500 mg/week or 850 mg every 2 weeks</td>
<td>Regular-release: 2,550 mg/day</td>
</tr>
<tr>
<td></td>
<td>Extended-release:</td>
<td>Extended-release: 2,000 mg/day</td>
</tr>
<tr>
<td></td>
<td>• Fortamet, Glumetza: 1,000 mg PO QD; increase as needed in increments of 500 mg/week</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glucophage XR: 500 mg PO QD; increase as needed in increments of 500 mg/week</td>
<td></td>
</tr>
<tr>
<td>Tradjenta (linagliptin)</td>
<td>5 mg PO QD</td>
<td>5 mg/day</td>
</tr>
<tr>
<td>Januvia (sitagliptin)</td>
<td>100 mg PO QD</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Segluromet (ertugliflozin/metformin)</td>
<td>Individualized dose PO BID</td>
<td>15/2,000 mg/day</td>
</tr>
<tr>
<td>Steglatro (ertugliflozin)</td>
<td>5 mg PO QD</td>
<td>15 mg/day</td>
</tr>
<tr>
<td>Janumet (sitagliptin/metformin)</td>
<td>Individualized dose PO BID</td>
<td>100/2,000 mg/day</td>
</tr>
<tr>
<td>Janumet XR (sitagliptin/metformin)</td>
<td>Individualized dose PO QD</td>
<td>100/2,000 mg/day</td>
</tr>
<tr>
<td>Jentadueto (linagliptin/metformin)</td>
<td>Individualized dose PO BID</td>
<td>5/2,000 mg/day</td>
</tr>
<tr>
<td>Jentadueto XR (linagliptin/metformin)</td>
<td>Individualized dose PO QD</td>
<td>5/2,000 mg/day</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/BoxedWarnings

- Contraindication(s):
  - History of serious hypersensitivity reaction to the requested drug product
  - Severe renal impairment (metformin-containing products and Glyxambi)
  - End-stage renal disease or dialysis (Glyxambi only)
  - Metabolic acidosis, including diabetic ketoacidosis (metformin-containing products only)
NYHA Class III or IV heart failure (*Oseni only*)
- Boxed warning(s): lactic acidosis (*metformin-containing products only*), congestive heart failure (*Oseni only*)

**Appendix D: General Information**
- A double-blind, placebo-controlled dose-response trial by Garber et al. found the maximal efficacy of metformin to occur at doses of 2,000 mg. However, the difference in adjusted mean change in HbA1c between the 1,500 and 2,000 mg doses was 0.3%, suggesting that the improvement in glycemic control provided by the additional 500 mg may be insufficient when HbA1c is > 7%.
- Per the 2019 American Diabetes Association (ADA) and American Association of Clinical Endocrinologists and 2019 American College of Endocrinology (AACE/ACE) guidelines:
  - Metformin is recommended for all patients with type 2 diabetes. Monotherapy is recommended for most patients; however:
    - Starting with dual therapy (i.e., metformin plus another agent, such as a sulfonylurea, thiazolidinedione, DPP-4 inhibitor, sodium-glucose co-transporter 2 [SGLT2] inhibitor, glucagon-like peptide 1 [GLP-1] receptor agonist, or basal insulin) may be considered for patients with baseline HbA1c ≥ 1.5% above their target per the ADA (≥ 7.5% per the AACE/ACE). According to the ADA, a reasonable HbA1c target for many non-pregnant adults is < 7% (≤ 6.5% per the AACE/ACE).
    - Starting with combination injectable therapy (i.e., with GLP-1 receptor agonist or insulin) may be considered for patients with baseline HbA1c ≥ 10% or ≥ 2% above their target per the ADA (> 9% if symptoms are present per the AACE/ACE).
  - If the target HbA1c is not achieved after approximately 3 months of monotherapy, dual therapy should be initiated. If dual therapy is inadequate after 3 months, triple therapy should be initiated. Finally, if triple therapy fails to bring a patient to goal, combination injectable therapy should be initiated. Each non-insulin agent added to initial therapy can lower HbA1c by 0.7-1%.
- According to the ADA, ASCVD includes coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin.

### V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyxambi (linagliptin/empagliflozin)</td>
<td>5/10 mg PO QD</td>
<td>5/25 mg/day</td>
</tr>
<tr>
<td>Nesina (alogliptin)</td>
<td>25 mg PO QD</td>
<td>25 mg/day</td>
</tr>
<tr>
<td>Onglyza (saxagliptin)</td>
<td>2.5 or 5 mg PO QD</td>
<td>5 mg/day</td>
</tr>
<tr>
<td>Trijardy XR (linagliptin/empagliflozin/metformin)</td>
<td>Individualized dose PO QD</td>
<td>5/25/2,000 mg/day</td>
</tr>
</tbody>
</table>

### VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyxambi (linagliptin/empagliflozin)</td>
<td>Tablets: 5/10 mg, 5/25 mg</td>
</tr>
<tr>
<td>Nesina (alogliptin)</td>
<td>Tablets: 6.25 mg, 12.5 mg, 25 mg</td>
</tr>
</tbody>
</table>
### VII. References


## Reviews, Revisions, and Approvals

| Removed requirement for failure of a formulary DPP-4 as all the agents in this guideline are on the formulary. Modified initial approval duration from 12 months to 6 months to allow for earlier assessment of therapeutic response. Added specific criteria surrounding required therapeutic response for re-auth. | 11.07.17 | 02.18 |
| Removed requirement for diagnosis Removed requirement for A1C submission Changed requirement for Metformin trial to be for 3 months without mandating a specific dose Allow first line use for members with A1C >= 9% References reviewed and updated Added requirement for Tradjenta trial prior to other agents. | 10.17.18 | |
| Per SDC: added diagnosis. Per LOB director: Added alternative DPP4 Januvia as accepted trial as this agent no longer require PA. Removed Onglyza from criteria, does not require PA. 1Q 2019 annual review: modified minimum A1c related for concurrent use of metformin from 9% to 8.5% based on 2019 ADA guidelines; references reviewed and updated. | 11.01.18 | 02.19 |
| Added requirement for trial of Steglatro or Segluromet prior to Glyxambi to align with criteria for Glyxambi in the SGLT2 clinical policy; members requesting other non-preferred DPP-4 inhibitors are still required to try/fail the preferred DPP-4 inhibitors Tradjenta and Januvia. | 04.22.19 |
| Per SDC and prior clinical guidance added Onglyza to criteria requiring redirection to the preferred DPP-4 inhibitors (sitagliptin or linagliptin-containing products, which include the addition of Janumet/XR and Jentadueto/XR); applied similar redirection to Nesina. 1Q 2020 annual review: no significant changes; added Trijardy XR with re-direction to Steglatro or Segluromet per SDC; references reviewed and updated. | 10.29.19 | 02.20 |
| Allowed bypass of Steglatro/Segluromet for patients with established cardiovascular disease or diabetic nephropathy requesting Glyxambi/Trijardy XR per previously approved clinical guidance and SDC clarification. | 04.01.20 |

### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or
remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.